The team behind TOXsIgN has invested considerable time, resources, and effort into collecting, curating, processing, developing, and maintaining this web resource.
×
TSP48833-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures after exposure to varespladib TSA203857-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib TSA203894-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib TSA203937-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib TSA203985-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib TSA204030-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib TSA204066-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib TSA204096-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib TSA204137-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib TSF439050-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.37 µM for 24.0 h 1 subfactor(s) TSF439051-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.125 µM for 24.0 h 1 subfactor(s) TSF439047-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 10.0 µM for 24.0 h 1 subfactor(s) TSF439048-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 3.33 µM for 24.0 h 1 subfactor(s) TSF439049-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 1.11 µM for 24.0 h 1 subfactor(s) TSF439052-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.04 µM for 24.0 h 1 subfactor(s) TSF540295-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 2.22 µM for 24.0 h 1 subfactor(s) TSF540296-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.74 µM for 24.0 h 1 subfactor(s) TSF540297-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.25 µM for 24.0 h 1 subfactor(s) TSF540298-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.08 µM for 24.0 h 1 subfactor(s) TSF540299-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.03 µM for 24.0 h 1 subfactor(s) TSF540300-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.01 µM for 24.0 h 1 subfactor(s) TSF439322-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 10.0 µM for 24.0 h 1 subfactor(s) TSF439325-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.37 µM for 24.0 h 1 subfactor(s) TSF439323-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 3.33 µM for 24.0 h 1 subfactor(s) TSF439324-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 1.11 µM for 24.0 h 1 subfactor(s) TSF439326-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.125 µM for 24.0 h 1 subfactor(s) TSF439327-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.04 µM for 24.0 h 1 subfactor(s) TSF540627-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.74 µM for 24.0 h 1 subfactor(s) TSF540626-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 2.22 µM for 24.0 h 1 subfactor(s) TSF540628-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.25 µM for 24.0 h 1 subfactor(s) TSF540629-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.08 µM for 24.0 h 1 subfactor(s) TSF540630-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.03 µM for 24.0 h 1 subfactor(s) TSF540631-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.01 µM for 24.0 h 1 subfactor(s) TSF439615-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.125 µM for 24.0 h 1 subfactor(s) TSF439611-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 10.0 µM for 24.0 h 1 subfactor(s) TSF439612-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 3.33 µM for 24.0 h 1 subfactor(s) TSF439613-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 1.11 µM for 24.0 h 1 subfactor(s) TSF439614-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.37 µM for 24.0 h 1 subfactor(s) TSF439616-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.04 µM for 24.0 h 1 subfactor(s) TSF540957-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.08 µM for 24.0 h 1 subfactor(s) TSF540954-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 2.22 µM for 24.0 h 1 subfactor(s) TSF540958-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.03 µM for 24.0 h 1 subfactor(s) TSF540955-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.74 µM for 24.0 h 1 subfactor(s) TSF540956-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.25 µM for 24.0 h 1 subfactor(s) TSF540959-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.01 µM for 24.0 h 1 subfactor(s) TSF439915-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 1.11 µM for 24.0 h 1 subfactor(s) TSF439913-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 10.0 µM for 24.0 h 1 subfactor(s) TSF439914-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 3.33 µM for 24.0 h 1 subfactor(s) TSF439918-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.04 µM for 24.0 h 1 subfactor(s) TSF439916-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.37 µM for 24.0 h 1 subfactor(s) TSF439917-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.125 µM for 24.0 h 1 subfactor(s) TSF440229-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 10.0 µM for 3.0 h 1 subfactor(s) TSF440230-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 3.33 µM for 3.0 h 1 subfactor(s) TSF440232-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.37 µM for 3.0 h 1 subfactor(s) TSF440231-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 1.11 µM for 3.0 h 1 subfactor(s) TSF440233-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.125 µM for 3.0 h 1 subfactor(s) TSF440234-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.04 µM for 3.0 h 1 subfactor(s) TSF541295-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.01 µM for 24.0 h 1 subfactor(s) TSF541290-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 2.22 µM for 24.0 h 1 subfactor(s) TSF541291-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.74 µM for 24.0 h 1 subfactor(s) TSF541292-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.25 µM for 24.0 h 1 subfactor(s) TSF541293-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.08 µM for 24.0 h 1 subfactor(s) TSF541294-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.03 µM for 24.0 h 1 subfactor(s) TSF541626-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 2.22 µM for 3.0 h 1 subfactor(s) TSF541627-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.74 µM for 3.0 h 1 subfactor(s) TSF541628-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.25 µM for 3.0 h 1 subfactor(s) TSF541629-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.08 µM for 3.0 h 1 subfactor(s) TSF541630-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.03 µM for 3.0 h 1 subfactor(s) TSF541631-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.01 µM for 3.0 h 1 subfactor(s) TSF440544-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 10.0 µM for 24.0 h 1 subfactor(s) TSF440545-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 3.33 µM for 24.0 h 1 subfactor(s) TSF440546-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 1.11 µM for 24.0 h 1 subfactor(s) TSF440547-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.37 µM for 24.0 h 1 subfactor(s) TSF440548-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.125 µM for 24.0 h 1 subfactor(s) TSF440549-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.04 µM for 24.0 h 1 subfactor(s) TSF541959-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.74 µM for 24.0 h 1 subfactor(s) TSF541958-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 2.22 µM for 24.0 h 1 subfactor(s) TSF541960-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.25 µM for 24.0 h 1 subfactor(s) TSF541961-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.08 µM for 24.0 h 1 subfactor(s) TSF541962-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.03 µM for 24.0 h 1 subfactor(s) TSF541963-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.01 µM for 24.0 h 1 subfactor(s) TSF440829-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.125 µM for 24.0 h 1 subfactor(s) TSF440825-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 10.0 µM for 24.0 h 1 subfactor(s) TSF440826-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 3.33 µM for 24.0 h 1 subfactor(s) TSF440827-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 1.11 µM for 24.0 h 1 subfactor(s) TSF440828-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.37 µM for 24.0 h 1 subfactor(s) TSF440830-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.04 µM for 24.0 h 1 subfactor(s) TSF542289-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.03 µM for 24.0 h 1 subfactor(s) TSF542285-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 2.22 µM for 24.0 h 1 subfactor(s) TSF542286-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.74 µM for 24.0 h 1 subfactor(s) TSF542287-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.25 µM for 24.0 h 1 subfactor(s) TSF542288-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.08 µM for 24.0 h 1 subfactor(s) TSF542290-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.01 µM for 24.0 h 1 subfactor(s) TSF441095-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.37 µM for 24.0 h 1 subfactor(s) TSF441096-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.125 µM for 24.0 h 1 subfactor(s) TSF441092-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 10.0 µM for 24.0 h 1 subfactor(s) TSF441093-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 3.33 µM for 24.0 h 1 subfactor(s) TSF441094-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 1.11 µM for 24.0 h 1 subfactor(s) TSF441097-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.04 µM for 24.0 h 1 subfactor(s) TSF542617-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 2.22 µM for 24.0 h 1 subfactor(s) TSF542618-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.74 µM for 24.0 h 1 subfactor(s) TSF542619-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.25 µM for 24.0 h 1 subfactor(s) TSF542620-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.08 µM for 24.0 h 1 subfactor(s) TSF542621-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.03 µM for 24.0 h 1 subfactor(s) TSF542622-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.01 µM for 24.0 h 1 subfactor(s) TSF441385-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 3.33 µM for 24.0 h 1 subfactor(s) TSF441386-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 1.11 µM for 24.0 h 1 subfactor(s) TSF441384-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 10.0 µM for 24.0 h 1 subfactor(s) TSF441387-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.37 µM for 24.0 h 1 subfactor(s) TSF441388-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.125 µM for 24.0 h 1 subfactor(s) TSF441389-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.04 µM for 24.0 h 1 subfactor(s) TSF542953-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 2.22 µM for 24.0 h 1 subfactor(s) TSF542954-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.74 µM for 24.0 h 1 subfactor(s) TSF542955-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.25 µM for 24.0 h 1 subfactor(s) TSF542956-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.08 µM for 24.0 h 1 subfactor(s) TSF542958-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.01 µM for 24.0 h 1 subfactor(s) TSF542957-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.03 µM for 24.0 h 1 subfactor(s) TSS439059-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.37 µM for 24.0 h TSS439060-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.125 µM for 24.0 h TSS439056-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 10.0 µM for 24.0 h TSS439057-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 3.33 µM for 24.0 h TSS439058-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 1.11 µM for 24.0 h TSS439061-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.04 µM for 24.0 h TSS540305-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 2.22 µM for 24.0 h TSS540306-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.74 µM for 24.0 h TSS540307-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.25 µM for 24.0 h TSS540308-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.08 µM for 24.0 h TSS540309-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.03 µM for 24.0 h TSS540310-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to varespladib 0.01 µM for 24.0 h TSS439331-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 10.0 µM for 24.0 h TSS439334-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.37 µM for 24.0 h TSS439332-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 3.33 µM for 24.0 h TSS439333-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 1.11 µM for 24.0 h TSS439335-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.125 µM for 24.0 h TSS439336-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.04 µM for 24.0 h TSS540637-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.74 µM for 24.0 h TSS540636-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 2.22 µM for 24.0 h TSS540638-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.25 µM for 24.0 h TSS540639-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.08 µM for 24.0 h TSS540640-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.03 µM for 24.0 h TSS540641-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to varespladib 0.01 µM for 24.0 h TSS439624-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.125 µM for 24.0 h TSS439620-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 10.0 µM for 24.0 h TSS439621-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 3.33 µM for 24.0 h TSS439622-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 1.11 µM for 24.0 h TSS439623-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.37 µM for 24.0 h TSS439625-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.04 µM for 24.0 h TSS540967-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.08 µM for 24.0 h TSS540964-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 2.22 µM for 24.0 h TSS540968-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.03 µM for 24.0 h TSS540965-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.74 µM for 24.0 h TSS540966-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.25 µM for 24.0 h TSS540969-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to varespladib 0.01 µM for 24.0 h TSS439924-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 1.11 µM for 24.0 h TSS439922-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 10.0 µM for 24.0 h TSS439923-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 3.33 µM for 24.0 h TSS439927-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.04 µM for 24.0 h TSS439925-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.37 µM for 24.0 h TSS439926-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.125 µM for 24.0 h TSS440238-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 10.0 µM for 3.0 h TSS440239-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 3.33 µM for 3.0 h TSS440241-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.37 µM for 3.0 h TSS440240-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 1.11 µM for 3.0 h TSS440242-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.125 µM for 3.0 h TSS440243-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.04 µM for 3.0 h TSS541305-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.01 µM for 24.0 h TSS541300-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 2.22 µM for 24.0 h TSS541301-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.74 µM for 24.0 h TSS541302-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.25 µM for 24.0 h TSS541303-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.08 µM for 24.0 h TSS541304-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.03 µM for 24.0 h TSS541636-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 2.22 µM for 3.0 h TSS541637-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.74 µM for 3.0 h TSS541638-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.25 µM for 3.0 h TSS541639-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.08 µM for 3.0 h TSS541640-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.03 µM for 3.0 h TSS541641-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to varespladib 0.01 µM for 3.0 h TSS440553-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 10.0 µM for 24.0 h TSS440554-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 3.33 µM for 24.0 h TSS440555-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 1.11 µM for 24.0 h TSS440556-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.37 µM for 24.0 h TSS440557-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.125 µM for 24.0 h TSS440558-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.04 µM for 24.0 h TSS541969-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.74 µM for 24.0 h TSS541968-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 2.22 µM for 24.0 h TSS541970-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.25 µM for 24.0 h TSS541971-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.08 µM for 24.0 h TSS541972-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.03 µM for 24.0 h TSS541973-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to varespladib 0.01 µM for 24.0 h TSS440838-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.125 µM for 24.0 h TSS440834-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 10.0 µM for 24.0 h TSS440835-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 3.33 µM for 24.0 h TSS440836-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 1.11 µM for 24.0 h TSS440837-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.37 µM for 24.0 h TSS440839-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.04 µM for 24.0 h TSS542299-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.03 µM for 24.0 h TSS542295-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 2.22 µM for 24.0 h TSS542296-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.74 µM for 24.0 h TSS542297-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.25 µM for 24.0 h TSS542298-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.08 µM for 24.0 h TSS542300-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to varespladib 0.01 µM for 24.0 h TSS441104-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.37 µM for 24.0 h TSS441105-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.125 µM for 24.0 h TSS441101-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 10.0 µM for 24.0 h TSS441102-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 3.33 µM for 24.0 h TSS441103-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 1.11 µM for 24.0 h TSS441106-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.04 µM for 24.0 h TSS542627-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 2.22 µM for 24.0 h TSS542628-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.74 µM for 24.0 h TSS542629-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.25 µM for 24.0 h TSS542630-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.08 µM for 24.0 h TSS542631-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.03 µM for 24.0 h TSS542632-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to varespladib 0.01 µM for 24.0 h TSS441394-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 3.33 µM for 24.0 h TSS441395-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 1.11 µM for 24.0 h TSS441393-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 10.0 µM for 24.0 h TSS441396-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.37 µM for 24.0 h TSS441397-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.125 µM for 24.0 h TSS441398-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.04 µM for 24.0 h TSS542963-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 2.22 µM for 24.0 h TSS542964-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.74 µM for 24.0 h TSS542965-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.25 µM for 24.0 h TSS542966-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.08 µM for 24.0 h TSS542968-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.01 µM for 24.0 h TSS542967-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to varespladib 0.03 µM for 24.0 h
TSP48833 - CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures after exposure to varespladib
Public
https://clue.io/data/CMap2020#LINCS2020
Experimental design
No experimental design provided
Results
No results provided